| 4th Apr 2023 10:30 am |
RNS |
HUTCHMED Initiates Registration Phase Enrollments |
| 31st Mar 2023 9:30 am |
RNS |
Total Voting Rights |
| 31st Mar 2023 7:00 am |
RNS |
Rolling Submission of Fruquintinib US NDA Complete |
| 14th Mar 2023 1:30 pm |
RNS |
Closing of Fruquintinib License to Takeda |
| 8th Mar 2023 8:30 am |
RNS |
Director's Share Dealing |
| 6th Mar 2023 8:30 am |
RNS |
Vesting of awards under the LTIP |
| 28th Feb 2023 12:15 pm |
RNS |
Publication of Form 20-F |
| 28th Feb 2023 8:30 am |
RNS |
2022 Full Year Results and Business Updates |
| 27th Feb 2023 10:00 am |
RNS |
Enrollment Completed in Phase 2 Amdizalisib trial |
| 31st Jan 2023 8:30 am |
RNS |
Notice of Results |
| 23rd Jan 2023 8:00 am |
RNS |
License to Takeda for Fruquintinib outside China |
| 18th Jan 2023 2:30 pm |
RNS |
Inclusion of ORPATHYS in NRDL in China |
| 3rd Jan 2023 8:30 am |
RNS |
Enrollment Completed in Phase 3 Trial |
| 30th Dec 2022 8:30 am |
RNS |
Blocklisting Six Monthly Return |
| 19th Dec 2022 10:00 am |
RNS |
FDA NDA Rolling Submission for Fruquintinib |
| 15th Nov 2022 7:00 am |
RNS |
HUTCHMED Announces Strategy Update |
| 14th Nov 2022 7:00 am |
RNS |
Positive Topline Phase 3 Result in Fruquintinib |
| 27th Oct 2022 12:30 pm |
RNS |
HUTCHMED Initiates Phase 2/3 Trial of Fruquintinib |
| 21st Oct 2022 9:30 am |
RNS |
Vesting of awards under the LTIP |
| 10th Oct 2022 9:30 am |
RNS |
Phase II/III Trial of Sovleplenib for in China |
| 30th Sep 2022 9:30 am |
RNS |
Total Voting Rights |
| 14th Sep 2022 11:00 am |
RNS |
Share Option Scheme and Long Term Incentive Plan |
| 8th Sep 2022 7:00 am |
RNS |
FRESCO-2 Colorectal Cancer MRCT Data Highlights |
| 23rd Aug 2022 10:00 am |
RNS |
Holding(s) in Company |
| 23rd Aug 2022 9:30 am |
RNS |
HUTCHMED To Present FRESCO-2 Data at ESMO 2022 |
| 9th Aug 2022 9:30 am |
RNS |
First Participant in Phase I Trial of IMG-004 |
| 8th Aug 2022 9:30 am |
RNS |
Preliminary results from SAVANNAH Phase 2 Trial |
| 8th Aug 2022 7:00 am |
RNS |
FRESCO-2 Study Has Met Primary Endpoint |
| 1st Aug 2022 12:04 pm |
RNS |
Interim Results and Business Updates |
| 1st Aug 2022 7:00 am |
RNS |
HUTCHMED Initiates Bridging Study of Tazemetostat |
| 15th Jul 2022 9:30 am |
RNS |
HUTCHMED Initiates Phase I Trial of HMPL-A83 |
| 13th Jul 2022 7:00 am |
RNS |
Results of SAVANNAH Global Phase II Trial at WCLC |
| 6th Jul 2022 7:00 am |
RNS |
First Participants in Phase I Trial of IMG-007 |
| 30th Jun 2022 9:30 am |
RNS |
Total Voting Rights |
| 29th Jun 2022 9:30 am |
RNS |
Blocklisting Six Monthly Return |
| 27th Jun 2022 9:30 am |
RNS |
HUTCHMED to Announce 2022 Half-Year Results |
| 1st Jun 2022 9:30 am |
RNS |
TAZVERIK® Approved in Hainan Pilot Zone |
| 24th May 2022 11:00 am |
RNS |
LTIP and Share Options |
| 16th May 2022 12:00 pm |
RNS |
Appointment of Non–Executive Director |
| 3rd May 2022 7:00 am |
RNS |
HUTCHMED Receives CRL from the US FDA |
